Human Pathology
Volume 41, Issue 12 , Pages 1702-1710 , December 2010

Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance

  • Anita Škrtić, MD

      Affiliations

    • Department of Pathology and Cytology, University of Zagreb, School of Medicine, University Hospital Merkur, 10000 Zagreb, Croatia
    • Corresponding Author InformationCorresponding author.
    • ,
  • Petra Korać, PhD

      Affiliations

    • Department of Pathology and Cytology, University of Zagreb, School of Medicine, University Hospital Merkur, 10000 Zagreb, Croatia
    • ,
  • Delfa Radić Krišto, MD

      Affiliations

    • Department of Medicine, University Hospital Merkur, 10000 Zagreb, Croatia
    • ,
  • Radmila Ajduković Stojisavljević, MD

      Affiliations

    • Department of Medicine, University Hospital Dubrava, 10000 Zagreb, Croatia
    • ,
  • Davor Ivanković, MD, PhD

      Affiliations

    • Department of Medical Statistics, Epidemiology and Medical Informatics, Andrija Stampar School of Public Health, University of Zagreb, School of Medicine, 10000 Zagreb, Croatia
    • ,
  • Mara Dominis, MD, PhD

      Affiliations

    • Department of Pathology and Cytology, University of Zagreb, School of Medicine, University Hospital Merkur, 10000 Zagreb, Croatia

Received 7 December 2009 ,Revised 27 April 2010 ,Accepted 7 May 2010.

References 

  1. Grogan TM, Van Camp B, Kyle RA, Muller-Hermelink HK, Harris NL. Plasma cell neoplasms. In:  Jaffe ES,  Harris NL,  Stein H,  Vardiman JW editor. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon (FR): IARC Press; 2001;
  2. Durie BG. Cellular and molecular genetic features of myeloma and related disorders. Hematol Oncol Clin North Am. 1992;6:463–477
  3. Salmon SE, Seligmann M. Plasma cell neoplasms. In:  De Vita VT,  Hellman S,  Rosenberg S editor. Cancer, principles and practice of Oncology. Philadelphia: J.B. Lippincott; 1998;p. 1854
  4. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–757
  5. Bartl R, Frisch B, Burkhardt R, et al. Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging. Br J Haematol. 1982;51:361–375
  6. Greipp PR, Leong T, Bennett JM, et al. Plasmablastic morphology–an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood. 1998;91:2501–2507
  7. Bartl R, Frisch B, Fateh-Moghadam A, Kettner G, Jaeger K, Sommerfeld W. Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol. 1987;87:342–355
  8. Brunning RD, McKenna RW. Plasma cell dyscrasias and related disorders. In: Atlas of Tumor Pathology. Washington, D.C.: Armed Forces Institute of Pathology; 1994;p. 323–369
  9. Chesi M, Bergsagel PL, Brents LA, Smith CM, Gerhard DS, Kuehl WM. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood. 1996;88:674–681
  10. González D, van der Burg M, García-Sanz R, et al. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood. 2007;110:3112–3121
  11. Bergsagel PL, Kuehl WM. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev. 2003;194:96–104
  12. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005;106:296–303
  13. Avet-Loiseau H, Facon T, Grosbois B, et al. Intergroupe Francophone du Myélome. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood. 2002;99:2185–2191
  14. Fonseca R, Bailey RJ, Ahmann GJ, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002;100:1417–1424
  15. Leong KG, Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood. 2006;107:2223–2233
  16. Milner LA, Bigas A. Notch as a mediator of cell fate determination in hematopoiesis: evidence and speculation. Blood. 1999;93:2431–2448
  17. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284:770–776
  18. Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell. 1991;66:649–661
  19. Houde C, Li Y, Song L, et al. Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood. 2004;104:3697–3704
  20. Jundt F, Pröbsting KS, Anagnostopoulos I, et al. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood. 2004;103:3511–3515
  21. Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood. 2004;103:3503–3510
  22. Morimura T, Goitsuka R, Zhang Y, Saito I, Reth M, Kitamura D. Cell cycle arrest and apoptosis induced by Notch1 in B cells. J Biol Chem. 2000;275:36523–36531
  23. Romer S, Saunders U, Jäck HM, Jehn BM. Notch1 enhances B-cell receptor-induced apoptosis in mature activated B cells without affecting cell cycle progression and surface IgM expression. Cell Death Differ. 2003;10:833–844
  24. Zweidler-McKay PA, He Y, Xu L, et al. Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies. Blood. 2005;106:3898–3906
  25. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842–854
  26. Smith A, Wisloff F, Samson D, UK Myeloma Forum  Nordic Myeloma Study Group, British Committee for Standards in Haematology . Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol. 2006;132:410–451
  27. UK Myeloma Forum , British Committee for Standards in Haematology . Diagnosis and management of multiple myeloma. Br J Haematol. 2001;115:522–540
  28. Olteanu H, Wang HY, Chen W, McKenna RW, Karandikar NJ. Immunophenotypic studies of monoclonal gammopathy of undetermined significance. BMC Clin Pathol. 2008;8:13
  29. Cook JR, His ED, Worley S, Tubbs RR, Hussein M. Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival. Am J Clin Pathol. 2006;125:615–624
  30. Ventura RA, Martin-Subero JI, Jones M, et al. FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn. 2006;8:141–151

PII: S0046-8177(10)00168-1

doi: 10.1016/j.humpath.2010.05.002

Human Pathology
Volume 41, Issue 12 , Pages 1702-1710 , December 2010

Article Tools

* Image Usage & Resolution